SyntheX

SyntheX is a private biotechnology company based in San Francisco, California, founded in 2016 by Charly Chahwan and Maria Soloveychik.

The company specializes in drug discovery using synthetic biology, focusing on identifying novel compounds that target previously undruggable protein targets. With a team of approximately 28 employees, SyntheX is dedicated to advancing precision drug discovery for cancer and rare diseases, having raised around $11.6 million in funding from notable investors. The company offers innovative drug discovery engines that utilize target-centric, cell-based functional selection. SyntheX operates two proprietary platforms: ToRPPIDO, which discovers disruptors of protein-protein interactions, and ToRNeDO, which identifies molecular glue-based protein degraders. Their technology, the ToRFLEx platform, employs genetically engineered circuits to find selective drugs that modulate challenging protein targets. SyntheX collaborates with pharmaceutical companies and research organizations, including a partnership with Bristol Myers Squibb to develop targeted protein degradation therapeutics.